HNSCC: Intratumoral Injection of T4 Immunotherapy Bypasses Homing – MedPage Today
|
HNSCC: Intratumoral Injection of T4 Immunotherapy Bypasses Homing
MedPage Today WASHINGTON — An intratumoral T4-immunotherapy with no preconditioning was safely administered to patients with advanced head and neck squamous cells carcinoma (HNSCC) at the highest dose tested, a dose-escalation Phase I trial showed. Disease … |
